You are here: Industry Insights > patients

News List

Patients waiting more than 18 weeks for surgery could double pharmatimes
May 08, 2017
The number of patients having to wait more than 18 weeks for elective procedures is expected to more than double by 2019 under the current status quo, according a document leaked to the HSJ.
CML patients in England win access to Incyte’s Iclusig pharmatimes
May 03, 2017
Chronic Myeloid Leukaemia (CML) patients in England who are resistant or intolerant to second generation tyrosine...
Camurus and Braeburn Announce Positive Top-line Results from Phase 3 Safety Study of CAM2038 americanpharmaceuticalreview
May 03, 2017
Camurus and Braeburn Pharmaceuticals announced positive top-line results from a long-term Phase 3 trial supporting the safety and efficacy of CAM2038 (weekly and monthly buprenorphine depots) in patients with moderate-to-severe opioid use disorder.
England's Cancer Drugs Fund 'failed to deliver meaningful value to patients and society' worldpharmanews
May 03, 2017
Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund (CDF) in England has shown that the fund was not good value for patients and society and may have resulted in patients suffering unnecessarily from toxic side effects of the dru
Quarter of cancer patients visit GP three times with no diagnosis pharmafile
April 26, 2017
A recent study, published in the British Journal of General Practice, has found that 23% of those suffering from ...
England “really is not a good place” to get cancer, BMS UK General Manager says pharmafile
April 25, 2017
Bristol-Myers Squibb’s UK General Manager Ben Hickey has slammed NICE over its assessment criteria and process in
Stroke patients in England to get ‘revolutionary’ procedure pharmatimes
April 14, 2017
Thousands of stroke patients in England are set to benefit from a “game-changing” new treatment that can significantly reduce the risk of long-term disability.
From bench to bedside – and back lilly
April 14, 2017
This article is from Susan Forda, Vice-President of Global Regulatory Affairs International at Lilly.
EU safety review backs continued use Uptravi for PAH pharmatimes
April 12, 2017
European regulators have ruled that Actelion’s Uptravi can continue to be used as per its prescribing information to treat...
NHS head and neck cancer patients barred from Opdivo pharmatimes
April 12, 2017
Cost regulators have ruled that Bristol-Myers Squibb’s immunotherapy Opdivo is too expensive for NHS use to treat head ...

Previous page 1 2 3 4 5 6 7 8 Next page